anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The subsequent 25 subjects enrolled into the study will be in the intervention group. Subjects accrued during the intervention phase will receive the verbal and written injection teaching, plus demonstration and return demonstration using an injection model. It is anticipated that the intervention teaching will take no longer then 5 additional minutes, however time will be evaluated as a secondary objective as well in both groups. The consented subjects will complete a questionnaire before the teaching, immediately after the teaching, and after performing the injection the following day. The nurse who administered the teaching will also complete an evaluation immediately following the teaching.
Provided herein are compositions for increasing Apolipoprotein L1 (ApoL1) in target cells. The ApoL1 can be a recombinant protein or an endogenous protein optionally in a ApoL1-containing complex. Antibodies and other binding molecules that specifically bind, Apolipoprotein L1 (ApoL1) and Haptoglobin related protein (Hpr). In preferred embodiments, the antibodies and other molecules bind to an ApoL1-containing complex such as a Trypanosome Lytic Factor (TLF), preferably under physiological conditions. In preferred embodiments, the antibodies and antigen binding fragments are bispecific, trispecific, and multispecific molecules that can bind to the ApoL1-containing complex and further bind to a cell specific antigen. Methods of using such molecules to increase flux of ApoL1- containing complexes into target cells expressing the cell specific antigen are also provided. Such increase in ApoL-containing complexes can increase cell death. In preferred embodiments, the target cells are cancer cells such as blood cancer cells or solid tumor cells.
Active drug put into 10-mg capsule form,,prepared by Clinical Center Pharmacy. Dose up to 120 mg daily, divided. Brand name Rilutek.
Therapy with probenecid should not be started until an acute gouty attack has subsided. However, if an acute attack is precipitated during therapy, probenecid may be continued without changing the dosage, and full therapeutic dosage of colchicine, or other appropriate therapy, should be given to control the acute attack.

The recommended adult dosage is 250 mg (½ probenecid tablet), twice a day for one week, followed by 500 mg (1 tablet) twice a day thereafter.

Some degree of renal impairment may be present in patients with gout. A daily dosage of 1000 mg may be adequate. However, if necessary, the daily dosage may be increased by 500 mg increments every 4 weeks within tolerance (and usually not above 2000 mg per day) if symptoms of gouty arthritis are not controlled or the 24 hour uric acid excretion is not above 700 mg. As noted, probenecid may not be effective in chronic renal insufficiency particularly when the glomerular filtration rate is 30 mL/minute or less.

Gastric intolerance may be indicative of overdosage, and may be corrected by decreasing the dosage.

As uric acid tends to crystallize out of an acid urine, a liberal fluid intake is recommended, as well as sufficient sodium bicarbonate (3 to 7.5 g daily), or potassium citrate (7.5 g daily) to maintain an alkaline urine (see PRECAUTIONS).

Alkalization of the urine is recommended until the serum urate level returns to normal limits and tophaceous deposits disappear, i.e., during the period when urinary excretion of uric acid is at a high level. Thereafter, alkalization of the urine and the usual restriction of purine-producing foods may be somewhat relaxed.

Probenecid should be continued at the dosage that will maintain normal serum urate levels. When acute attacks have been absent for 6 months or more and serum urate levels remain within normal limits, the daily dosage may be decreased by 500 mg every 6 months. The maintenance dosage should not be reduced to the point where serum urate levels tend to rise.
Patients who were consented, completed the accommodations survey, but for whom a medical student was not available during the time of the patient's procedure will serve as our control group. The controls will fill out both an accommodations survey before and a patient satisfaction survey after the procedure. No ambassador will be assigned for the procedure day. The investigators hope to enroll 25 controls.
Participants were to receive alphanate 100 International Units (IU/kg/day) for up to 33 months in Immune tolerance induction (ITI) Treatment Phase. The dose could be increased up to 200 IU/kg/day based on Investigator's discretion. Following ITI Treatment Phase, participants were to enter the Prophylactic Phase where alphanate dose was to be tapered down in a step wise manner to reach a final prophylactic dose of 50 IU/kg every other day or 3 times per week, at the investigator's discretion.
The Active comparator group will take part in the Mindfulness and Self-compassion (MBSC) programme (3 sessions). MBSC will be facilitated by two accredited mindfulness practitioners, who are also qualified social workers. Sessions will be supplemented by brief homework activities.
BACKGROUND: Patients with rheumatoid arthritis (RA) showed impaired immune tolerance characterized by reduced follicular regulatory T (Tfr) cells, and they also exhibited altered gut microbiotas and their metabolites in RA. However, the association of gut microbiotas and their metabolites with the immune tolerance mediated by Tfr cells in RA remains unclear.
METHODS: Peripheral blood and stool samples were collected from 32 new-onset RA patients and 17 healthy controls (HCs) in the Second Hospital of Shanxi Medical University between January 2022 and June 2022. The peripheral blood was used to detect the circulating regulatory T (Treg), helper T(Th)17, Tfr, and follicular helper T (Tfh) cells by modified flow cytometry. The stool samples were used to analyze the gut microbiotas and their metabolites via 16S rDNA sequencing and metabolomic profiling. We aimed to characterize the gut microbiotas and their metabolites in RA and identified their association with Tfr cell-mediated immune tolerance.
RESULTS: The new-onset RA demonstrated reduced Treg and Tfr cells, associated with the disease activity and autoantibodies. There were significant differences in gut microbiotas between the two groups as the results of β diversity analysis (P = 0.039) including 21 differential gut microbiotas from the phylum to genus levels. In which, Ruminococcus 2 was associated with the disease activity and autoantibodies of RA, and it was identified as the potential biomarker of RA [area under curve (AUC) = 0.782, 95% confidence interval (CI) = 0.636-0.929, P = 0.001]. Eleven differential metabolites were identified and participated in four main pathways related to RA. Arachidonic acid might be the potential biomarker of RA (AUC = 0.724, 95% CI = 0.595-0.909, P = 0.038), and it was the core metabolite as the positive association with six gut microbiotas enriched in RA. The reduced Tfr cells were associated with the altered gut microbiotas and their metabolites including the Ruminococcus 2, the arachidonic acid involved in the biosynthesis of unsaturated fatty acid pathway and the 3-methyldioxyindole involved in the tryptophan metabolism pathway.
CONCLUSION: The breakdown of immune tolerance mediated by reduced Tfr cells was associated with the altered gut microbiotas and their metabolites implying the possible mechanism of RA pathogenesis from the perspective of microecology-metabolism-immune.
Electroencephalography (EEG) signal has been recognized as an effective fatigue detection method, which can intuitively reflect the drivers' mental state. However, the research on multi-dimensional features in existing work could be much better. The instability and complexity of EEG signals will increase the difficulty of extracting data features. More importantly, most current work only treats deep learning models as classifiers. They ignored the features of different subjects learned by the model. Aiming at the above problems, this paper proposes a novel multi-dimensional feature fusion network, CSF-GTNet, based on time and space-frequency domains for fatigue detection. Specifically, it comprises Gaussian Time Domain Network (GTNet) and Pure Convolutional Spatial Frequency Domain Network (CSFNet). The experimental results show that the proposed method effectively distinguishes between alert and fatigue states. The accuracy rates are 85.16% and 81.48% on the self-made and SEED-VIG datasets, respectively, which are higher than the state-of-the-art methods. Moreover, we analyze the contribution of each brain region for fatigue detection through the brain topology map. In addition, we explore the changing trend of each frequency band and the significance between different subjects in the alert state and fatigue state through the heat map. Our research can provide new ideas in brain fatigue research and play a specific role in promoting the development of this field.
The United States is in the midst of a drug overdose crisis: the rate of substance use, overdose, and substance abuse-related economic costs is rapidly increasing. Despite the prevalence of Substance Abuse Disorder (SUD), only 10% of SUD patients receive treatment. The initial link into care is often one of the hardest barriers to overcome due to wait times, complex systems to navigate, and fluctuating motivation. Hospitalization is often a time when patients are more receptive to SUD treatment. One potential effective treatment approach is peer recovery support services. Currently at Greenville Memorial Hospital, there is no direct link between hospitalization and outpatient care for patients with SUD, making it difficult to start or continue the recovery process. Thus, the goal of this study is to evaluate the impact of the initiation of peer recovery services during hospitalization on addiction severity and quality of life. By establishing a successful inpatient link to recovery treatment, this study may lead to the development of an effective method of care that can readily be implemented into the healthcare system.
Combined allergic rhinitis and asthma syndrome (CARAS) is an airway-type 2 immune response with a profuse inflammatory process widely affecting the world population. Due to the compromise of quality of life and the lack of specific pharmacotherapy, the search for new molecules becomes relevant. This study aimed to evaluate the effectiveness of the Morita-Bailys-Hillman adduct (CISACN) treatment in the CARAS experimental model. Female BALB/c mice were ovalbumin (OVA) -sensitized and -challenged and treated with CISACN. The treatment decreased the eosinophil migration to the nasal and lung cavities and tissues and the goblet cell hyperplasia/hypertrophy, attenuated airway hyperactivity by reducing the hyperplasia/hypertrophy of the smooth muscle and the extracellular matrix's thickness. Also, the treatment reduced the clinical signs of rhinitis as nasal rubbing and sneezing in a histamine-induced nasal hyperreactivity assay. The immunomodulatory effect of CISACN was by reducing OVA-specific IgE serum level, and IL-33, IL-4, IL-13, and TGF-β production, dependent on IFN-γ increase. Furthermore, the effect of CISACN on lung granulocytes was by decreasing the p-p38MAPK/p65NF-κB signaling pathway. Indeed, CISACN reduced the p38MAPK and p65NF-κB activation. These data demonstrated the anti-inflammatory and immunomodulatory effects of the CISACN with scientific support to become a pharmacological tool to treat airway inflammatory diseases.
UNLABELLED: Evaluation of guidelines in actual practice is a crucial step in guideline improvement. A retrospective evaluation of the Dutch guideline for children with fever without an apparent source (FWS) showed 50% adherence in young infants. We prospectively evaluated adherence to the Dutch guideline and its impact on management in current practice. Prospective observational multicenter cross-sectional study, including children 3 days to 16 years old presented for FWS at one of seven emergency departments in participating secondary and tertiary care hospitals in the Netherlands. Adherence to the Dutch FWS guideline, adapted from the National Institute for Health and Care Excellence (NICE) guideline, was evaluated, and patterns in non-adherence and the impact of non-adherence on clinical outcomes and resource use were explored. Adherence to the guideline was 192/370 (52%). Adherence was lowest in patients categorized as high risk for severe infection (72/187, 39%), compared to the low-risk group (64/73, 88%). Differences in adherence were significant between risk categories (P < 0.001) but not between age categories. In case of non-adherence, less urinalysis, fewer bacterial cultures (blood, urine, and cerebral spinal fluid), and less empirical antibiotic treatment were performed (P < 0.050). Clinical outcomes were not significantly different between the non-adherence and the adherence group, particularly regarding missed severe infections.
CONCLUSIONS: We found a high non-adherence rate of 48%, which did not lead to unfavorable clinical outcomes. This substantiates the need for a critical reevaluation of the FWS guideline and its indications for bacterial cultures, viral testing, and antibiotic treatment.
WHAT IS KNOWN: • Despite the development of national guidelines, variation in practice is still substantial in the assessment of febrile children to distinguish severe infection from mild self-limiting disease. • Previous retrospective research suggests low adherence to national guidelines for febrile children in practice.
WHAT IS NEW: • In case of non-adherence to the Dutch national guideline, similar to the National Institute for Health and Care Excellence (NICE) guideline from the United Kingdom, physicians have used fewer resources than the guideline recommended without increasing missed severe infections.
This research has developed isotope-labeled liposomes, which performs a significant ability to emit radiations such as alpha particle and gmma ray for cancer therapy. The preparation procedures include: (1) Passive encapsulation: an extruder, ultrasonic bath, or ultrasonic probe to prepare large unilamellar and small unilamellar liposomes. Isotopes such as indium 111, Actinium 225 were added to lipid suspension before extrusion or sonication. (2) Active encapsulation: chelators like EDTA, DTPA, and DOTA were first encapsulated in liposomes, free chelators were removed by a size exclude column (SEC). Then, ionphores and isotopes were added to liposome solution sequences. Isotopes were Alpha emitter isotope-labeled liposomes for cancer therapy.
PURPOSE: A MASCC/ISOO Clinical Practice Statement (CPS) is aimed at generating a concise tool for clinicians that concentrates practical information needed for the management of oral complications of cancer patients. This CPS raises awareness to the prevention of medication-related osteonecrosis of the jaw (MRONJ) in patients with breast cancer treated with adjuvant bone-modifying agents (BMA).
METHODS: This CPS was developed based on a critical evaluation of the literature followed by a structured discussion of a group of leading experts, members of the Oral Care Study Group of MASCC/ISOO. The information is presented in the form of succinct bullets and tables to generate a short manual about the best standard of care.
RESULTS: In patients treated with adjuvant BMA, dento-alveolar surgery poses a moderate risk for MRONJ that ranges between the high risk for MRONJ in patients with metastatic breast cancer and the low risk for MRONJ in patients with osteoporosis. Existing MRONJ guidelines serve as a starting point for adjuvant BMA use. Urgent procedures should be delivered without delay using the accepted precautions to prevent MRONJ. If elective surgery is considered, the individual risk for MRONJ following surgery should be assessed according to common risk factors.
CONCLUSION: Prevention of MRONJ in primary breast cancer patients treated with adjuvant BMA requires risk-benefit assessment; collaboration between the medical team, dental professional, and patient; and patient-specific tailored dental treatment planning. The patient should be informed about this risk. Additional research is needed to define optimal MRONJ care for this population.
PURPOSE: A composition for preventing and treating atopic dermatitis is provided to prevent acute systemic anaphylaxis by mast cell degranulator and to suppress skin blood vessel leakage. CONSTITUTION: A composition for preventing and treating atopic dermatitis contains rose petal extract or Ganoderma lucidum culture product. The rose petal extract is obtained by adding rose petals in 3-15 times purified water and extracting at 80-120°C. The rose petal extract is also obtained by adding ethanol and extracting at 50-70°C for 1-3 hours. The Ganoderma lucidum culture is obtained by heating at 110-130°C for 10-60 minutes, culturing for 4-5 days, and freeze-drying at -30°C to -10°C. The composition is used in the form of beverage, powder, or ointment.
Green light at 500 lux. Participants will view 545 nm green light delivered via a portable battery-operated ganzfeld light stimulation device for 2 hours per day for 5 consecutive days.
PURPOSE: Pain after open urological procedures is often intense. The aim of the study was to compare the efficacy of intrathecal morphine with systemic analgesia approaches.
DESIGN: Prospective, randomized, single-blind controlled study.
METHODS: Patients undergoing open prostatectomy or nephrectomy were randomly divided into the intervention group or the control group. Patients in the intervention group received morphine 250 mcg in 2.5 mL saline intrathecally. Anesthesia was identical in both groups. All patients were admitted to the intensive care unit (ICU) postoperative and received paracetamol 1 g intravenously every 6 hours and diclofenac 75 mg intramuscularly every 12 hours. If postoperative pain exceeded four on the numeric rating scale, morphine 10 mg was administered subcutaneously. Pain intensity, time to first dose of morphine, morphine doses, and side effects were recorded.
FINDINGS: In total, 41 patients were assigned to the intervention group and 57 to the control group. The time to administration of the first dose of morphine was significantly (P < .001) longer in the intervention group when compared to controls. This observation was also noted individually for patients undergoing nephrectomy (36.86 hours vs 4.06 hours) and prostatectomy (33.13 hours vs 4.5 hours). Many patients did not need opioids after surgery in the intervention group (nephrectomy 72% vs 3%, prostatectomy 75% vs 4.5%, P < .001). There was no significant difference in the incidence of side effects.
CONCLUSIONS: The results of our study confirmed that preoperative intrathecal morphine provides long-lasting analgesia and reduces the need for postoperative systemic administration of opioids. Adverse effects are minor and comparable between groups.
Women assigned to use MMB 2.0, along with NorthShore HealthSystem's well established usual care, will be guided by the program to move sequentially through 6 sessions, one of which becomes available for use each week, while interacting with engaging activities within each session along with recommended practice activities to encourage transfer of learning and skills to everyday routines. Content is presented using text, interactions, animations, and videos. MMB includes daily tracking and charting of mood and pleasant activities as well as online access to a library, covering a range of issues of concern to pregnant women and new mothers. Integrated text messages offer both motivational messages and links to access specific portions of session content in the MMB 2.0 program. The study coordinator will also provide up to 3 supportive coaching calls to each woman in the MMB 2.0 condition. These calls complement and thus are adjunctive to the MMB 2.0 program.
The invention relates to an application of a PHA-L (Phaseolus vulgaris-Leucoagglutinin) phytolectin in radio-resistive effect and a pharmaceutical composition preparation taking PHA-L as a main active component. The radio-resistive effect of the PHA-L phytolectin belongs to the application technology in the field of medicines. The invention in particular relates to the application of PHA-L in preparing medicines for preventing and treating radiation damage and auxiliary treatment of tumor radiation. The invention discloses the research results of the PHA-L phytolectin in radio-resistive pharmacology and activity of anti-oxidative damage. The research of pharmacological activity of the PHA-L shows that the PHA-L has a remarkable effect for treating radiation damage and pharmacological activities such as the effect of increasing leukocytes to leucopenia. The PHA-L phytolectin is expected to be developed as a novel efficient radio-resistive medicine and a medicine for auxiliary treatment of tumor radiation.
Patients receive azacitidine SC QD on days 1-10. Treatment repeats every 28 days for 6-24 courses in the absence of disease progression or unacceptable toxicity.
PURPOSE:To obtain a cosmetic, rich in ultraviolet protecting ability and having high transparency with hardly any paleness. CONSTITUTION:This cosmetic is obtained by blending titanium tetraisopropoxide (TTIP) and an amorphous type ultrafine particulate titanium oxide, subjected to the compounding treatment and obtained by a simultaneous vapor hydrolytic method of a polysiloxane expressed by formula I [R1 is OCH3, OC2H5, C3H7 or H; the average value of (n) is 1-4], formula II [R2 is OCH3, OC2H5, OC3H7 or H; the average value of (m) is 3-8] or formula III and having 7-40nm average particle diameter. The amount of the polysiloxane is 1-40 pts.wt., preferably 5-30 pts.wt. based on 100 pts.wt. TTIP. The ultrafine particulate titanium oxide is prepared by evaporating, e.g. an alkoxide of titanium, excess water and a polysiloxane, producing the amorphous type ultrafine particulate titanium oxide by the hydrolysis of the alkoxide of titanium in the same reactor and simultaneously carrying out the compounding treatment of the surface of the titanium oxide with the polysiloxane.
BACKGROUND: The COVID-19 pandemic has significantly impacted frontline health workers. However, a neglected dimension of this discourse was the extent to which the pandemic impacted frontline healthcare workers providing non-communicable diseases (NCDs) care. This study aims to understand the experiences of healthcare workers with no prior exposure to pandemics who provided care to people living with NCDs (PLWNCDs).
METHODS: A qualitative study design was employed, using a face-to-face in-depth interviews. Interviews were conducted in primary healthcare facilities in three administrative regions of Ghana, representing the Northern, Southern and Middle Belts. Only frontline health workers with roles in providing care for PLWNCDs were included. Purposive snowballing and convenience sampling methods were employed to select frontline health workers. An open-ended interview guide was used to facilitate data collection, and thematic content analysis was used to analyse the data.
RESULTS: A total of 47 frontline health workers were interviewed. Overall, these workers experienced diverse patient-driven and organisational challenges. Patient-level challenges included a decline in healthcare utilisation, non-adherence to treatment, a lack of continuity, fear and stigma. At the organisational levels, there was a lack of medical logistics, increased infection of workers and absenteeism, increased workload and burnout, limited motivational packages and inadequate guidelines and protocols. Workers coped and responded to the pandemic by postponing reviews and consultations, reducing inpatient and outpatient visits, changing their prescription practices, using teleconsultation and moving to long-shift systems.
CONCLUSION: This study has brought to the fore the experiences that adversely affected frontline health workers and, in many ways, affected the care provided to PLWNCDs. Policymakers and health managers should take these experiences into account in plans to mitigate the impact of future pandemics.